1. Morrish, JN, Wang, SL, Stevens, KL, et al. Mortality and causes of death in the WHO multinational study of vascular disease in diabetes. Diabetologia 2001; 44: S14–S21.
Google Scholar | Crossref | Medline | ISI2. Zinman, B, Wanner, C, Lachin, JM, et al. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med 2015; 373: 2117–2128.
Google Scholar | Crossref | Medline | ISI3. Cowie, MR, Fisher, M. SGLT2 inhibitors: mechanisms of cardiovascular benefit beyond glycaemic control. Nat Rev Cardiol 2020; 17: 761–772.
Google Scholar | Crossref | Medline4. Neal, B, Perkovic, V, Mahaffey, KW, et al. Canagliflozin and cardiovascular and renal events in type 2 diabetes. N Engl J Med 2017; 377: 644–657.
Google Scholar | Crossref | Medline | ISI5. Wiviott, SD, Raz, I, Bonaca, MP, et al. Dapagliflozin and cardiovascular outcomes in type 2 diabetes. N Engl J Med 2018; 380: 347–357.
Google Scholar | Crossref | Medline6. Packer, M, Anker, SD, Butler, J, et al. Cardiovascular and renal outcomes with empagliflozin in heart failure. N Engl J Med 2020; 383: 1413–1424.
Google Scholar | Crossref | Medline7. Lin, B, Koibuchi, N, Hasegawa, Y, et al. Glycemic control with empagliflozin, a novel selective SGLT2 inhibitor, ameliorates cardiovascular injury and cognitive dysfunction in obese and type 2 diabetic mice. Cardiovasc Diabetol 2014; 13: 148.
Google Scholar | Crossref | Medline8. Kannel, WB, McGee, DL. Diabetes and cardiovascular disease: the Framingham study. JAMA 1979; 241: 2035–2038.
Google Scholar | Crossref | Medline | ISI9. Murthy, VL, Naya, M, Foster, CR, et al. Association between coronary vascular dysfunction and cardiac mortality in patients with and without diabetes mellitus. Circulation 2012; 126: 1858–1868.
Google Scholar | Crossref | Medline | ISI10. Levelt, E, Rodgers, CT, Clarke, WT, et al. Cardiac energetics, oxygenation, and perfusion during increased workload in patients with type 2 diabetes mellitus. Eur Heart J 2015; 37: 3461–3469.
Google Scholar | Crossref | Medline11. Bratis, K, Child, N, Terrovitis, J, et al. Coronary microvascular dysfunction in overt diabetic cardiomyopathy. IJC Metab Endocr 2014; 5: 19–23.
Google Scholar | Crossref12. Larghat, AM, Swoboda, PP, Biglands, JD, et al. The microvascular effects of insulin resistance and diabetes on cardiac structure, function, and perfusion: a cardiovascular magnetic resonance study. Eur Heart J Cardiovasc Imaging 2014; 15: 1368–1376.
Google Scholar | Crossref | Medline13. Rubler, S, Dlugash, J, Yuceoglu, YZ, et al. New type of cardiomyopathy associated with diabetic glomerulosclerosis. Am J Cardiol 1972; 30: 595–602.
Google Scholar | Crossref | Medline | ISI14. Swoboda, PP, McDiarmid, AK, Erhayiem, B, et al. Diabetes mellitus, microalbuminuria, and subclinical cardiac disease: identification and monitoring of individuals at risk of heart failure. J Am Heart Assoc 2017; 6: e005539.
Google Scholar | Crossref | Medline15. Wong, TC, Piehler, KM, Kang, IA, et al. Myocardial extracellular volume fraction quantified by cardiovascular magnetic resonance is increased in diabetes and associated with mortality and incident heart failure admission. Eur Heart J 2014; 35: 657.
Google Scholar | Crossref | Medline16. Asbun, J, Villarreal, FJ. The pathogenesis of myocardial fibrosis in the setting of diabetic cardiomyopathy. J Am Coll Cardiol 2006; 47: 693–700.
Google Scholar | Crossref | Medline | ISI17. Eguchi, K, Boden-Albala, B, Jin, Z, et al. Association between diabetes mellitus and left ventricular hypertrophy in a multiethnic population. Am J Cardiol 2008; 101: 1787–1791.
Google Scholar | Crossref | Medline18. Taskiran, M, Fritz-Hansen, T, Rasmussen, V, et al. Decreased myocardial perfusion reserve in diabetic autonomic neuropathy. Diabetes 2002; 51: 3306–3310.
Google Scholar | Crossref | Medline19. Jellis, CL, Sacre, JW, Wright, J, et al. Biomarker and imaging responses to spironolactone in subclinical diabetic cardiomyopathy. Eur Heart J Cardiovasc Imaging 2014; 15: 776–786.
Google Scholar | Crossref | Medline20. Gulati, A, Japp, AG, Raza, S, et al. Absence of myocardial fibrosis predicts favorable long-term survival in new-onset heart failure. Circ Cardiovasc Imaging 2018; 11: e007722.
Google Scholar | Crossref | Medline21. Rubinshtein, R, Yang, EH, Rihal, CS, et al. Coronary microcirculatory vasodilator function in relation to risk factors among patients without obstructive coronary disease and low to intermediate Framingham score. Eur Heart J 2009; 31: 936–942.
Google Scholar | Crossref | Medline22. Hudsmith, LE, Petersen, SE, Tyler, DJ, et al. Determination of cardiac volumes and mass with FLASH and SSFP cine sequences at 1.5 vs. 3 Tesla: a validation study. J Magn Reson Imaging 2006; 24: 312–318.
Google Scholar | Crossref | Medline | ISI23. Gulsin, GS, Swarbrick, DJ, Hunt, WH, et al. Relation of aortic stiffness to left ventricular remodeling in younger adults with type 2 diabetes. Diabetes 2018; 67: 1395.
Google Scholar | Crossref | Medline24. Levelt, E, Mahmod, M, Piechnik, SK, et al. Relationship between left ventricular structural and metabolic remodelling in type 2 diabetes mellitus. Diabetes 2016; 65: 44–52.
Google Scholar | Medline | ISI25. Bluemke, DA, Kronmal, RA, Lima, JAC, et al. The relationship of left ventricular mass and geometry to incident cardiovascular events: the MESA study. J Am Coll Cardiol 2008; 52: 2148–2155.
Google Scholar | Crossref | Medline | ISI26. Khan, JN, Wilmot, EG, Leggate, M, et al. Subclinical diastolic dysfunction in young adults with Type 2 diabetes mellitus: a multiparametric contrast-enhanced cardiovascular magnetic resonance pilot study assessing potential mechanisms. Eur Heart J Cardiovasc Imaging 2014; 15: 1263–1269.
Google Scholar | Crossref | Medline27. Ernande, L, Rietzschel, ER, Bergerot, C, et al. Impaired myocardial radial function in asymptomatic patients with type 2 diabetes mellitus: a speckle-tracking imaging study. J Am Soc Echocardiogr 2010; 23: 1266–1272.
Google Scholar | Crossref | Medline | ISI28. Levelt, E, Pavlides, M, Banerjee, R, et al. Ectopic and visceral fat deposition in lean and obese patients with type 2 diabetes. J Am Coll Cardiol 2016; 68: 53–63.
Google Scholar | Crossref | Medline29. Finck, BN, Lehman, JJ, Leone, TC, et al. The cardiac phenotype induced by PPARα overexpression mimics that caused by diabetes mellitus. J Clin Invest 2002; 109: 121–130.
Google Scholar | Crossref | Medline | ISI30. Gulick, T, Cresci, S, Caira, T, et al. The peroxisome proliferator-activated receptor regulates mitochondrial fatty acid oxidative enzyme gene expression. Proc Natl Acad Sci USA 1994; 91: 11012–11016.
Google Scholar | Crossref | Medline | ISI31. Leone, TC, Weinheimer, CJ, Kelly, DP. A critical role for the peroxisome proliferator-activated receptor α (PPARα) in the cellular fasting response: the PPARα-null mouse as a model of fatty acid oxidation disorders. Proc Natl Acad Sci USA 1999; 96: 7473–7478.
Google Scholar | Crossref | Medline | ISI32. Wu, P, Inskeep, K, Bowker-Kinley, MM, et al. Mechanism responsible for inactivation of skeletal muscle pyruvate dehydrogenase complex in starvation and diabetes. Diabetes 1999; 48: 1593.
Google Scholar | Crossref | Medline33. Jia, G, Hill, MA, Sowers, JR. Diabetic cardiomyopathy. Circ Res 2018; 122: 624–638.
Google Scholar | Crossref | Medline34. Haak, T, Hanaire, H, Ajjan, R, et al. Flash glucose-sensing technology as a replacement for blood glucose monitoring for the management of insulin-treated type 2 diabetes: a multicenter, open-label randomized controlled trial. Diabetes Ther 2017; 8: 55–73.
Google Scholar | Crossref | Medline | ISI35. Solini, A, Giannini, L, Seghieri, M, et al. Dapagliflozin acutely improves endothelial dysfunction, reduces aortic stiffness and renal resistive index in type 2 diabetic patients: a pilot study. Cardiovasc Diabetol 2017; 16: 138–138.
Google Scholar | Crossref | Medline36. Kang, S, Verma, S, Teng, G, et al. Direct effects of empagliflozin on extracellular matrix remodeling in human cardiac fibroblasts: novel translational clues to EMPA-REG OUTCOME. Can J Cardiol 2017; 33: S169.
Google Scholar | Crossref37. Green, JB, Bethel, MA, Armstrong, PW, et al. Effect of sitagliptin on cardiovascular outcomes in type 2 diabetes. N Engl J Med 2015; 373; 232–242.
Google Scholar | Crossref | Medline | ISI38. White, WB, Cannon, CP, Heller, SR, et al. Alogliptin after acute coronary syndrome in patients with type 2 diabetes. N Engl J Med 2013; 369: 1327–1335.
Google Scholar | Crossref | Medline | ISI39. Stanley, WC, Lopaschuk, GD, McCormack, JG. Regulation of energy substrate metabolism in the diabetic heart. Cardiovasc Res 1997; 34: 25–33.
Google Scholar | Crossref | Medline | ISI40. Kellman, P, Hansen, MS, Nielles-Vallespin, S, et al. Myocardial perfusion cardiovascular magnetic resonance: optimized dual sequence and reconstruction for quantification. J Cardiovasc Magn Reson 2017; 19: 43.
Google Scholar | Crossref | Medline41. Karamitsos, T, Hudsmith, L, Selvanayagam, J, et al. Operator induced variability in left ventricular measurements with cardiovascular magnetic resonance is improved after training. J Cardiovasc Magn Reson 2007; 9: 777–783.
Google Scholar | Crossref | Medline42. Ugander, M, Oki, AJ, Hsu, L-Y, et al. Extracellular volume imaging by magnetic resonance imaging provides insights into overt and sub-clinical myocardial pathology. Eur Heart J 2012; 33: 1268–1278.
Google Scholar | Crossref | Medline43. Swoboda, PA-O, Erhayiem, B, Kan, R, et al. Cardiovascular magnetic resonance measures of aortic stiffness in asymptomatic patients with type 2 diabetes: association with glycaemic control and clinical outcomes. Cardiovasc Diabetol 2018; 17: 35.
Google Scholar | Crossref | Medline44. Von Scholten, BJ, Hasbak, P, Christensen, TE, et al. Cardiac 82Rb PET/CT for fast and non-invasive assessment of microvascular function and structure in asymptomatic patients with type 2 diabetes. Diabetologia 2016; 59: 371–378.
Google Scholar | Crossref | Medline | ISI45. Verma, S, McMurray, JJV, Cherney, DZI. The metabolodiuretic promise of sodium-dependent glucose cotransporter 2 inhibition: the search for the sweet spot in heart failure. JAMA Cardiol 2017; 2: 939–940.
Google Scholar | Crossref | Medline46. Sattar, N, McLaren, J, Kristensen, SL, et al. SGLT2 Inhibition and cardiovascular events: why did EMPA-REG Outcomes surprise and what were the likely mechanisms? Diabetologia 2016; 59: 1333–1339.
Google Scholar |